Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
US Department of Justice
Novartis
Boehringer Ingelheim
Federal Trade Commission
Express Scripts
Daiichi Sankyo
Cipla
Teva

Generated: January 18, 2018

DrugPatentWatch Database Preview

Actelion Pharms Company Profile

« Back to Dashboard

Summary for Actelion Pharms
International Patents:214
US Patents:18
Tradenames:7
Ingredients:7
NDAs:8

Drugs and US Patents for Actelion Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-008 Dec 21, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-002 Dec 21, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Actelion Pharms Ltd TRACLEER bosentan TABLET;ORAL 021290-002 Nov 20, 2001 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-008 Dec 21, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-008 Dec 21, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-003 Dec 21, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-003 Dec 21, 2015 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-004 Dec 21, 2015 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-004 Dec 21, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-006 Dec 21, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Actelion Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Actelion Pharms Ltd ZAVESCA miglustat CAPSULE;ORAL 021348-001 Jul 31, 2003 ➤ Subscribe ➤ Subscribe
Actelion Pharms Ltd ZAVESCA miglustat CAPSULE;ORAL 021348-001 Jul 31, 2003 ➤ Subscribe ➤ Subscribe
Actelion Pharms Ltd TRACLEER bosentan TABLET;ORAL 021290-002 Nov 20, 2001 ➤ Subscribe ➤ Subscribe
Actelion Pharms Ltd TRACLEER bosentan TABLET;ORAL 021290-001 Nov 20, 2001 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Actelion Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,440,931 Form-III crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide and use thereof ➤ Subscribe
7,285,549 Sulfamides and their use as endothelin receptor antagonists ➤ Subscribe
8,809,334 Therapeutic compositions containing macitentan ➤ Subscribe
2,013,210,830 ➤ Subscribe
2,010,029,783 ➤ Subscribe
8,664,278 Stabilized compositions of volatile alkylating agents and methods of using thereof ➤ Subscribe
8,501,817 Stabilized compositions of alkylating agents and methods of using same ➤ Subscribe
9,597,331 Therapeutic compositions containing macitentan ➤ Subscribe
9,340,516 Form-II crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl) acetamide, method for producing the same, and use thereof ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Actelion Pharms Drugs

Supplementary Protection Certificates for Actelion Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017000059 Germany ➤ Subscribe PRODUCT NAME: CHLORMETHIN; REGISTRATION NO/DATE: EU/1/16/1171 20170303
/2016 Austria ➤ Subscribe PRODUCT NAME: SELEXIPAG ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1083 (MITTEILUNG) 20160519
0836 Netherlands ➤ Subscribe PRODUCT NAME: SELEXIPAG OF EEN ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/15/1083 20160519
2 Finland ➤ Subscribe
266 Luxembourg ➤ Subscribe PRODUCT NAME: SELEXIPAG OU UN SEL DE CELUI-CI; FIRST REGISTRATION DATE: 20160519
00672 Netherlands ➤ Subscribe PRODUCT NAME: MACITENTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/13/893/001-003 20131220
2016000077 Germany ➤ Subscribe PRODUCT NAME: SELEXIPAG ODER SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1083/001-010 20160512
2017026 Lithuania ➤ Subscribe PRODUCT NAME: CHLORMETINAS; REGISTRATION NO/DATE: EU/1/16/1171 20170303
C0042 France ➤ Subscribe PRODUCT NAME: SELEXIPAG OU L'UN DE SES SELS; REGISTRATION NO/DATE: EU/1/15/1083 20160519
/2017 Austria ➤ Subscribe PRODUCT NAME: CHLORMETHIN; REGISTRATION NO/DATE: EU/1/16/1171 (MITTEILUNG) 20170307
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Healthtrust
Julphar
Express Scripts
QuintilesIMS
Dow
AstraZeneca
US Army
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot